A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

ClinicalTrials.gov ID: NCT00089947

Public ClinicalTrials.gov record NCT00089947. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Prospective, Phase 2 Study Comparing Thymoglobulin in a Rapid Discontinuation of Corticosteroids Protocol With Standard Corticosteroid Therapy in Living Donor Renal Transplantation Using Mycophenolate Mofetil and Tacrolimus Maintenance Therapy

Study identification

NCT ID: NCT00089947
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Genzyme, a Sanofi Company; Industry
Enrollment: 150 participants

Conditions and interventions

Conditions

Interventions

Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)] Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2003
Primary completion: Nov 30, 2005
Completion: Nov 30, 2005
Last update posted: Mar 17, 2015

2003 – 2005

United States locations

U.S. sites: 19
U.S. states: 14
U.S. cities: 16

Facility	City	State	ZIP	Site status
University of Arkansas for Medical Science	Little Rock	Arkansas	72205	—
Keck USC School of Medicine	Los Angeles	California	90033	—
University of California, Los Angeles Medical Center	Los Angeles	California	90095	—
University of California, San Diego Medical Center	San Diego	California	92103	—
California Pacific Medical Center	San Francisco	California	94115	—
University of California, San Francisco	San Francisco	California	94143	—
University of Colorado Health Sciences Center	Denver	Colorado	80262	—
Emory University	Atlanta	Georgia	30322	—
Indiana University	Indianapolis	Indiana	46202	—
Oschner Medical Center	New Orleans	Louisiana	70121	—
Johns Hopkins University Hospital	Baltimore	Maryland	21287	—
Saint Barnabas Medical Center	Livingston	New Jersey	07039	—
Mount Sinai School of Medicine	New York	New York	10029	—
Duke University Medical Center	Durham	North Carolina	27710	—
Christ Hospital	Cincinnati	Ohio	45219	—
University of Cincinnati Medical Center	Cincinnati	Ohio	45267	—
Texas Transplant Institute	San Antonio	Texas	78229	—
Medical College of Virginia	Richmond	Virginia	23298	—
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00089947, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 17, 2015 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00089947 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →